Breaking News, Collaborations & Alliances

BioMarin Receives Pfizer Milestone Payments

Totaling $20 million, the payments were triggered by the FDA's acceptance of Pfizer's NDA for talazoparib

BioMarin Pharmaceutical Inc. has received $20 million in milestone payments from Pfizer.  These milestone payments were triggered by the FDA’s acceptance of Pfizer’s New Drug Application (NDA) submission for talazoparib and by the European Medicines Agency (EMA) acceptance of Pfizer’s submission of a Marketing Authorization Application (MAA) for talazoparib. The payments are part of an agreement made with Medivation, Inc. when the company purchased talazoparib.  Medivation...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters